The effect of nebulized furosemide and salbuthamol on dyspnea in chronic obstructive pulmonary disease

A comparison between nebulized furosemide and salbuthamol on dyspnea improvment in chronic obstructive pulmonary disease patients reffered to shahid beheshti hospital

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201707126187N5

Enrollment

Registered

2017-08-25

Start date

2014-02-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CHRONIC OBSTRUCTIVE PULMONARY DISEASE. Chronic obstructive pulmonary disease, unspecified

Interventions

Intervention 1: salbuthamol 2.5 mg. Intervention 2: furosemide40 mg nebulizer.

Treatment - Drugs

salbuthamol 2.5 mg

furosemide40 mg nebulizer

Eligibility

Sex/Gender

All

Age

40 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with chronic obstructive pulmonary disease based on their spirometry who had dyspnea according to class 3-5 mmrc Exclusion criteria: Advanced heart failure; Severe osteoarthritis; Inability to walking;Tracheal stenosis

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
DYSPNEA. Timepoint: 5 minute after nebulizer. Method of measurement: questionair.	—

Secondary

Measure	Time frame
FEV1. Timepoint: 15 minute after nebulizer. Method of measurement: spirometry.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mohammadali Saba

Kashan University of Medical Sciences

mohammadali_saba@yahoo.comsaba-ma@kaums.ac.ir+98 36 13523

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026